AS1907417, a novel GPR119 agonist, as an insulinotropic and β-cell preservative agent for the treatment of type 2 diabetes

Biochemical and Biophysical Research Communications

Volumn 400, Issue 4, 2010, Pages 745-751

  Yoshida, Shigeru ^a   Tanaka, Hirotsugu ^a   Oshima, Hiroyuki ^a   Yamazaki, Takao ^a   Yonetoku, Yasuhiro ^a   Ohishi, Takahide ^a   Matsui, Tetsuo ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

AS1907417; Glucose stimulated insulin secretion; GPR119 agonist; Pancreatic cell function; Small molecule; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; AS 1907417; CYCLIC AMP; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; MESSENGER RNA; PYRIMIDINE DERIVATIVE; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; EMBRYO; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROMOTER REGION; SINGLE DRUG DOSE;

ANIMALS; CYCLIC S-OXIDES; CYTOPROTECTION; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED STRAINS; PROMOTER REGIONS, GENETIC; PYRIMIDINES; RATS; RATS, ZUCKER; RECEPTORS, G-PROTEIN-COUPLED;

MUS; RATTUS;

EID: 77957274682     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.08.141     Document Type: Article

References (20)

1. DeFronzo R.A., Bonadonna R.C., Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1999, 15:318-368.
2. Taylor S.I., Accili D., Imai Y. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?. Diabetes 1994, 43:735-740.
3. Meece J. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. Curr. Med. Res. Opin. 2007, 23:933-944.
4. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
5. Ross S.A., Ekoé J.M. Incretin agents in type 2 diabetes. Can. Fam. Physician 2010, 56:639-648.
6. Chu Z.L., Jones R.M., He H., Carroll C., Gutierrez V., Lucman A., Moloney M., Gao H., Mondala H., Bagnol D., Unett D., Liang Y., Demarest K., Semple G., Behan D.P., Leonard J. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007, 148:2601-2609.
7. Sakamoto Y., Inoue H., Kawakami S., Miyawaki K., Miyamoto T., Mizuta K., Itakura M. Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochem. Biophys. Res. Commun. 2006, 351:474-480.
8. Drucker D.J. Glucagon-like peptide. Diabetes 1998, 47:159-169.
9. Yip R.G., Wolfe M.M. GIP biology and fat metabolism. Life Sci. 2000, 66:91-103.
10. Soga T., Ohishi T., Matsui T., Saito T., Matsumoto M., Takasaki J., Matsumoto S., Kamohara M., Hiyama H., Yoshida S., Momose K., Ueda Y., Matsushime H., Kobori M., Furuichi K. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem. Biophys. Res. Commun. 2005, 28:744-751.
11. Overton H.A., Babbs A.J., Doel S.M., Fyfe M.C., Gardner L.S., Griffin G., Jackson H.C., Procter M.J., Rasamison C.M., Tang-Christensen M., Widdowson P.S., Williams G.M., Reynet C. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell. Metab. 2006, 3:167-175.
12. Chu Z.L., Jones R.M., He H., Carroll C., Gutierrez V., Lucman A., Moloney M., Gao H., Mondala H., Bagnol D., Unett D., Liang Y., Demarest K., Semple G., Behan D.P., Leonard J. A role for intestinal endocrine cell-expressed GPR119 in glycemic control by enhancing GLP-1 and GIP release. Endocrinology 2008, 149:2038-2047.
13. Jones R.M., Leonard J.N., Buzard D.J., Lehmann J. GPR119 agonists for the treatment of type 2 diabetes. Expert Opin. Ther. Pat. 2009, 19:1339-1359.
14. S. Yoshida, T. Ohishi, T. Matsui, M. Shibasaki, Identification of a novel GPR119 agonist, AS1269574, with in vitro and in vivo glucose-stimulated insulin secretion. Biochem. Biophys. Res. Commun., in press.
15. Sander M., Griffen S.C., Huang J., German M.S. A novel glucose-responsive element in the human insulin gene functions uniquely in primary cultured islets. Proc. Natl. Acad. Sci. USA 1998, 95:11572-11577.
16. Brubaker P.L., Drucker D.J. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology 2004, 145:2653-2659.
17. Perfetti R., Zhou J., Doyle M.E., Egan J.M. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000, 141:4600-4605.
18. Li Y., Hansotia T., Yusta B., Ris F., Halban P.A., Drucker D.J. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J. Biol. Chem. 2003, 278:471-478.
19. Cerf M.E. Transcription factors regulating β-cell function. Eur. J. Endocrinol. 2006, 155:671-679.
20. Wyne K.L. Free fatty acids and type 2 diabetes mellitus. Am. J. Med. 2003, 115(Suppl. 8A):29S-36S.